Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]

Acute Myeloid Leukemia Refractory Clinical Trial

— AML-NET  

Official title:

A Phase I/II Study to Evaluate the Safety Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination With Standard AZACITIDINE+ VENETOCLAX in Patients With Refractory Acute Myeloid Leukemia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06150040
• Other study ID #: ET23-026
• Secondary ID: EU number
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: December 4, 2023
• Est. completion date: November 30, 2027

Study information

• Verified date: September 2023
• Source: Centre Leon Berard
• Contact: Anne-Sophie MICHALET, MD
• Phone: 4 78 78 26 41
• Email: anne-sophie.michallet[@]lyon.unicancer.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to investigate the safety and the clinical activities of NP137 when combined with Azacitidine and Venetoclax in patients with refractory acute myeloid leukemia after 2 cycles of Azacitidine and Venetoclax.

Description:

The dual treatment, VENETOCLAX and AZACITIDINE, is the standard of care for patients with newly diagnosed AML who are ineligible for intensive chemotherapy. However, upfront resistance as well as relapse following initial response demonstrate the need to improve this therapeutic strategy.

NP137 is a first-in-class humanized monoclonal antibody targeting specifically and selectively Netrin-1. Based on data collected from non clinical studies NP137 should act in synergy with VENETOCLAX and AZACITIDINE to reactivate and enhance the apoptotic pathway in AML cells.

The herein proposed study to assess the safety (Safety run in/ phase I part) and the preliminary efficacy signal (extension phase II part) of the NP137 when combined to AZACITIDINE AND VENETOCLAX in patients with refractory acute myeloid leukemia after 2 cycles of Azacitidine and Venetoclax.

This study will be an open-label, Phase I/II trial. the first part, consists to a safety run to assess the security and the tolerability of the drugs combination from the first 6 to 12 first patients enrolled into the study. All patients will receive a fixed dose of NP137 at the RP2D (Recommended Phase 2 Dose) determined from the First in human NP137 study(DL1) . A dose deescalation of NP137 is planned to DL-1 according to the Dose Limiting Toxicities observed during this period. The second part will be will be then conducted as a phase II using an adaptive Bayesian approach allowing to quickly stop treatment without evidence of efficacy. The clinical activity will be assessed based on ELN (European LeukemiaNet) criteria 2027 for the Acute Myeloid Leukemia.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 35
• Est. completion date: November 30, 2027
• Est. primary completion date: March 28, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

I1. Adult is = 65 years of age at the time of signing the ICF (Inform Consent Form)

I2. Histologically confirmed acute myeloid leukemia (AML) as defined by the 2022 World Health Organization (WHO) Classification.

I3. Patient previously untreated for AML (except with the first 2 cycles of his/her current A+V treatment) and who is considered as ineligible for induction regimen and intensive chemotherapy due to age and other comorbidity that the physician judges to be incompatible with such treatment:

OR Patient with expected poor prognosis under intensive /induction chemotherapy (e.g. with complex karyotype) OR "No-go" patients according ALFA decision tool ([e.i: patient with Adverse cytogenetics =1 of the following: mKRAS, mTP53)

Note : Patients with favourable-risk cytogenetics with intensive chemotherapy are not eligible, such as:

• t(8;21)(q22;q22.1); RUNX1-RUNX1T1

• inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11

• Mutated NPM1 without FLT3-ITD or with FLT3-ITDlow†

• Biallelic mutated CEBPA

I4. Patients under treatment by A+V treatment as standard first line treatment for AML with no CR nor CRi after 2 cycles of AZACITIDINE +VENETOCLAX.

I5. Patient must be, in the judgment of the investigator, an appropriate candidate for an experimental therapy i.e. with no available other standard treatment or options except palliative care.

I6. Participant must have a life expectancy of at least 12 weeks.

I7. Participants has with Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 are eligible to the safety run-in part whatever their age. Then for the expansion part, patient with ECOG PS (Performance Status) of 0 to 2 for subject = 75 years OR of 0 to 3 for subject = 65 to 74 years of age are eligible.

I8. Demonstrate adequate cardiac function:

• QTc (corrected QT interval) =470ms

• Resting systolic BP <160mmHg

• Resting diastolic BP <100mmHg

• LVEF (left ventricular ejection fraction) =50% as determined by multiple-gated acquisition (MUGA) scan or transthoracic echocardiogram.

I9. Demonstrate adequate organ function as defined in table below, all screening laboratory tests should be performed within 7 days prior Cycle 1 day 1 :

• White Blood Cells Count < 25 × 109/L or lower; use of leukapheresis or hydroxyurea is permitted to achieve this concentration before Cycle 1 Day 1, at the discretion of the treating physician and according to institutional practice. (see exclusion criteria E6)

• Creatinine clearance Calculated creatinine clearance =30 mL/min determined by the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula OR via urine collection for 24-hour creatinine clearance or serum creatinine = 2 upper limit of normal (ULN)

• Bilirubin Total bilirubin < 2 × the upper limit of normal (ULN) If total bilirubin = 2 ULN, Direct Bilirubin must be < 2 x ULN unless considered due to leukemic organ involvement(< 5 ULN) and with the following Exception: Patients with known Gilbert disease who have serum bilirubin level = 3 ULN may be enrolled.

• SGOT (serum glutamate oxaloacetate transaminase) (AST) and SGPT (serum glutamate pyruvate transaminase) (ALT) = 3 x ULN unless considered due to leukemic organ involvement (< 5 ULN)

I10. Patient has no evidence of spontaneous tumor lysis syndrome (TLS) before NP137 introduction.

I11. Female subjects must be either:

• Postmenopausal; defined no menses for = 12 months without an alternative medical cause; OR

• Permanently surgically sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy)

I12. Non-sterile male subjects must use contraceptive methods with partner(s) prior to beginning study drug administration and continuing up to 3.5 months [106 days] after the last dose of NP137. Male subjects must agree to refrain from sperm donation from initial study drug administration during this same period.

I13. Patient must understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures.

I14. Patient must be able and willing to comply with study visits and procedures as per protocol.

I15. Patients must be covered by a medical insurance

Exclusion Criteria:

E1. Patient who is eligible for any curative therapy including but not limited to induction / intensive chemotherapies, CAR-T cell therapy and agrees to receive this therapy.

E2. Patient previously treated for AML with a hypomethylating agent and/or other chemotherapeutic agents either conventional or experimental for AML before NP137 introduction.

E3. Patient who has acute promyelocytic leukemia.

E4. Patient who experienced:

• Any persisting non hematological grade = 3 AZACITIDINE AND VENETOCLAX related Adverse events before C1D1.

• Any vascular disorder grade = 3 within 6 months prior C1D1.

E5. History of severe allergic anaphylactic reactions (= grade 3) to one of the components of the study drugs or to humanized antibodies or premedication and/or any of their excipients.

E6. Prior therapy or needs to be treated with a forbidden concomitant/concurrent therapies/procedures including:

• Any investigational agent or have used an investigational device.

• Major surgery within 4 weeks of start of study treatment. Participants must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment, C1D1.

• Anti-cancer treatment other than those specified in the protocol i.e. AZACITIDINE + VENETOCLAX.

• Live or live-attenuated vaccine within 30 days prior to the first dose of study treatments. Note: Inactivated vaccine are allowed.

Note:

• During the safety run in phase, Hydroxyurea is authorized prior C1D1 but a wash-out period of 2 days or 5*t1/2 before C1D1 whatever • shorter is required.

• During the expansion phase, the use of hydroxyurea for patients with rapidly proliferative disease is allowed during the course of cycle 1 at the discretion of the treating physician and according to institutional practice

E7. Active or untreated central nervous system involvement.

E8. Other invasive malignancy in the last 2 years except for those with a minimal risk of metastasis or death such as adequately managed in-situ carcinoma of the cervix, basal or squamous cell skin cancer, localized prostate cancer or ductal carcinoma in situ treated with curative intent, previous malignancy confined and surgically resected (or treated with other modalities) with curative intent.

E9. Patients with any other known concurrent severe and/or uncontrolled medical condition including but not limited to diabetes, cardiovascular disease including hypertension, renal disease, or active uncontrolled infection, which could compromise participation in the study. For active infection requiring systemic therapy or fever likely secondary to infection within prior 48 hours: prophylactic antibiotics or prolonged course of IV antibiotics for controlled infection are allowed.

E10. Patients with uncontrolled hypertension despite adequate medical therapy, active and uncontrolled congestive heart failure New York Heart Association (NYHA) class III/IV, clinically significant and uncontrolled arrhythmia as judged by the treating physician.

E11. Patient with evidence of uncontrolled active infection requiring systemic therapy (viral, bacterial or fungal).

E12. Patients known to be positive to HIV (testing will be performed a screening).

E13. Patients known to be positive for hepatitis B or C infection with the exception of those with an undetectable viral load within 3 months. Hepatitis B or C testing is not required and subjects with serologic evidence of prior vaccination to Hepatitis B virus (i.e., HBs Ag, anti-HBs+ and anti-HBc-) may participate.

Patients placed under a legal protection regimen: Judicial Safeguards, curatorship or guardianship.

Related Conditions & MeSH terms

• Acute Myeloid Leukemia Refractory
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

Intervention

Drug:
• NP137
IV infusion, 14mg/kg or 9mg/kg, every 2 weeks
• Azacitidine Injection
Subcutaneous injection, 75 mg/m², on cycle Days 1-7 (28-days cycle)
• Venetoclax
Orally, 70 mg, every day on Days 1-28

Locations

Country	Name	City	State
France	Centre Léon Bérard	Lyon

Sponsors (2)

Lead Sponsor	Collaborator
Centre Leon Berard	NETRIS Pharma

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety run in part : Incidence of Dose Limiting Toxicities (DLT)	To assess the safety of the proposed therapeutic combination [NP137 + AZACITIDINE VENETOCLAX] according to the incidence of Dose Limiting Toxicities (DLT) as defined per protocol.	4 weeks
Primary	Phase II part : Objective Response Rate (ORR)	To investigate the clinical activity of the proposed therapeutic combination [NP137 + AZACITIDINE + VENETOCLAX] through the Objective Response Rate (ORR) over the 4 cycles of AZACITIDNE +VENETOCLAX+ NP137 administration.; ORR will be defined as the proportion of patients with a complete remission (CR) or complete remission with incomplete hematologic recovery (CRi), as best overall response over the 4 cycles of the study combination.	16 weeks
Secondary	Adverse events	Incidence of any adverse events graded according to NCI-CTCAE V5.0	from the date of first intake of study drug until to 90 days after study drug discontinuation, (at least up to 12 months for the last patient in)
Secondary	Duration of response	Measurement of the duration of response (CR/CRi)	from the time of first documented response until the first progression or death, (at least up to 12 months for the last patient in)
Secondary	Best overall response (BOR)	Best overall response, is determined by the best response designation. For subjects without documented progression or subsequent anticancer therapy, all available response designations will contribute to the BOR determination :from the date of first intake of study drug until progression or at time of initiation of a new anti-cancer treatment	Every 28 days, up to 1 year
Secondary	Objective Response Rate	Objective Response Rate after 2 cycles of study treatment defined as the proportion of participants who achieve: complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) after 2 cycles of treatment (2 cycles of A+V including 4 injections of NP137)	8 weeks
Secondary	Overall survival	Overall survival measured from the date of treatment start to the date of death from any cause; patients not known to have died at last follow-up are censored on the date they were last known to be alive.	Until up to 1 year follow-up of the last patient enrolled
Secondary	Progression Free survival	Progression Free survival defined as the time from the initiation of the study treatment until first evidence of disease treatment failure : from the date of first intake of study drug until progression	Every 28 days, up to 1 year follow-up of the last patient enrolled
Secondary	Treatment Failure	Time to Treatment Failure Rate (TTF) defined as the time from the initiation of study treatment to its early discontinuation. Reasons for prematurely discontinuing treatment can include cancer progression but also adverse events, patient choice, or death.	Continuously, up to 1 year follow-up of the last patient enrolled
Secondary	Death in Medullary Aplasia	Death in Medullary Aplasia Rate based on cytological assessment: Deaths occurring =7 days following completion of initial treatment while cytopenic, with an aplastic or hypoplastic bone marrow obtained within 7 days of death, without evidence of persistent leukemia.	Every 28 days, up to 1 year follow-up of the last patient enrolled
Secondary	Neutrophil / platelet count recovery	Time to neutrophil / platelet count recovery (absolute neutrophil count (ANC) > 1 × 109/L (defined as neutrophil recovery) and platelet count > 100 × 109/L (defined as platelet recovery)).	Continuously, up to 1 year follow-up of the last patient enrolled
Secondary	Pharmacokinetic parameter: Cmax	Plasma peak concentration	Cycle 1 day 1, pre-dose; cycle 1 day 1, 3hours post-dose; cycle 1 day 2; cycle 1 day 7 or day 8; cycle 1 day 15, pre-dose; cycle 7 day 1, pre-dose; if Grade =3 infusion-related reaction and at the end of treatment visit (each cycle is 28 days)
Secondary	Pharmacokinetic parameter: tmax	Time to reach the peak concentration	Cycle 1 day 1, pre-dose; cycle 1 day 1, 3hours post-dose; cycle 1 day 2; cycle 1 day 7 or day 8; cycle 1 day 15, pre-dose; cycle 7 day 1, pre-dose; if Grade =3 infusion-related reaction and at the end of treatment visit (each cycle is 28 days)
Secondary	Pharmacokinetic parameter: AUCt (Area under the concentration-time)	Area under the concentration-time curve from time zero to the last sample with the quantifiable concentration	Cycle 1 day 1, pre-dose; cycle 1 day 1, 3hours post-dose; cycle 1 day 2; cycle 1 day 7 or day 8; cycle 1 day 15, pre-dose; cycle 7 day 1, pre-dose; if Grade =3 infusion-related reaction and at the end of treatment visit (each cycle is 28 days)
Secondary	Pharmacokinetic parameter: AUC8 (Area under the concentration-time)	Area under the concentration-time curve from time zero to infinity corresponding to the definite integral of a curve that describes the variation of a drug concentration in blood plasma as a function of time (drug exposure in plasma)	Cycle 1 day 1, pre-dose; cycle 1 day 1, 3hours post-dose; cycle 1 day 2; cycle 1 day 7 or day 8; cycle 1 day 15, pre-dose; cycle 7 day 1, pre-dose; if Grade =3 infusion-related reaction and at the end of treatment visit (each cycle is 28 days)
Secondary	Pharmacokinetic parameter: CL (Clearance)	Clearance: volume of plasma from which NP137 is completely removed per unit time.	Cycle 1 day 1, pre-dose; cycle 1 day 1, 3hours post-dose; cycle 1 day 2; cycle 1 day 7 or day 8; cycle 1 day 15, pre-dose; cycle 7 day 1, pre-dose; if Grade =3 infusion-related reaction and at the end of treatment visit (each cycle is 28 days)
Secondary	Pharmacokinetic parameter: t1/2	Terminal elimination half-life: time required for the amount of NP137 in the body to decrease by half.	Cycle 1 day 1, pre-dose; cycle 1 day 1, 3hours post-dose; cycle 1 day 2; cycle 1 day 7 or day 8; cycle 1 day 15, pre-dose; cycle 7 day 1, pre-dose; if Grade =3 infusion-related reaction and at the end of treatment visit (each cycle is 28 days)